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ABSTRACT Escherichia coli sequence type 410 (ST410) has been reported world-
wide as an extraintestinal pathogen associated with resistance to ﬂuoroquinolones,
third-generation cephalosporins, and carbapenems. In the present study, we investi-
gated national epidemiology of ST410 E. coli isolates from Danish patients. Further-
more, E. coli ST410 was investigated in a global context to provide further insight
into the acquisition of the carbapenemase genes blaOXA-181 and blaNDM-5 of this suc-
cessful lineage. From 127 whole-genome-sequenced isolates, we reconstructed an
evolutionary framework of E. coli ST410 which portrays the antimicrobial-resistant
clades B2/H24R, B3/H24Rx, and B4/H24RxC. The B2/H24R and B3/H24Rx clades
emerged around 1987, concurrently with the C1/H30R and C2/H30Rx clades in E. coli
ST131. B3/H24Rx appears to have evolved by the acquisition of the extended-
spectrum -lactamase (ESBL)-encoding gene blaCTX-M-15 and an IncFII plasmid, en-
coding IncFIA and IncFIB. Around 2003, the carbapenem-resistant clade B4/H24RxC
emerged when ST410 acquired an IncX3 plasmid carrying a blaOXA-181 carbapen-
emase gene. Around 2014, the clade B4/H24RxC acquired a second carbapenemase
gene, blaNDM-5, on a conserved IncFII plasmid. From an epidemiological investigation
of 49 E. coli ST410 isolates from Danish patients, we identiﬁed ﬁve possible regional
outbreaks, of which one outbreak involved nine patients with blaOXA-181- and
blaNDM-5-carrying B4/H24RxC isolates. The accumulated multidrug resistance in E. coli
ST410 over the past two decades, together with its proven potential of transmission
between patients, poses a high risk in clinical settings, and thus, E. coli ST410 should
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be considered a lineage with emerging “high-risk” clones, which should be moni-
tored closely in the future.
IMPORTANCE Extraintestinal pathogenic Escherichia coli (ExPEC) is the main cause of
urinary tract infections and septicemia. Signiﬁcant attention has been given to the
ExPEC sequence type ST131, which has been categorized as a “high-risk” clone.
High-risk clones are globally distributed clones associated with various antimicrobial
resistance determinants, ease of transmission, persistence in hosts, and effective
transmission between hosts. The high-risk clones have enhanced pathogenicity and
cause severe and/or recurrent infections. We show that clones of the E. coli ST410
lineage persist and/or cause recurrent infections in humans, including bloodstream
infections. We found evidence of ST410 being a highly resistant globally distributed
lineage, capable of patient-to-patient transmission causing hospital outbreaks. Our
analysis suggests that the ST410 lineage should be classiﬁed with the potential to
cause new high-risk clones. Thus, with the clonal expansion over the past decades
and increased antimicrobial resistance to last-resort treatment options, ST410 needs
to be monitored prospectively.
KEYWORDS BEAST, epidemiology, Escherichia coli, outbreak, evolution, high-risk
clone
Escherichia coli sequence type 131 (ST131) is a high-risk clone, deﬁned as (i) globallydistributed, (ii) associated with multiple antimicrobial resistance determinants,
(iii) able to colonize and persist in hosts for more than 6 months, (iv) capable of effective
transmission between hosts, (v) having enhanced pathogenicity and ﬁtness, and (vi)
able to cause severe and/or recurrent infections (1). ST131 is associated with a steady
increase in antimicrobial resistance globally, including ﬂuoroquinolone, third-
generation cephalosporin, and carbapenem resistance (2–4). A recent study of 10
extended-spectrum -lactamase (ESBL)-producing E. coli ST410 isolates from Germany
provided preliminary evidence that this lineage includes a new successful clone
with cross-sectorial transmission between wildlife, humans, companion animals,
and the environment (5, 6). This high-risk potential is supported by two recent
reports from China (7) and Italy (8) of ST410 isolates carrying the acquired carbap-
enemase gene blaOXA-181. Similarly, ST410 carrying blaOXA-181 has also been shown
to be involved in a small hospital outbreak in Denmark (9). Recent complete-
genome sequencing of an ST410 isolate from a Danish patient further revealed a
multidrug-resistant strain with two carbapenemase genes (blaOXA-181 and blaNDM-5)
carried on IncX3 and IncF plasmids, respectively (10). Several studies on molecular
characterization of carbapenemase-producing Enterobacteriaceae (CPE) among inpa-
tients have indicated clonal spread of CPE from patient to patient (11, 12). Carbapen-
emase genes are often located on mobile elements containing multiple resistance
genes (13, 14), leading to potential horizontal transfer to other bacterial species. The
mortality associated with invasive infections caused by CPE is high (15), making the
spread of CPE an immense clinical concern. As ST410 has been increasingly reported
worldwide, it is important to determine whether the ST410 lineage is causing new
pandemic high-risk clones similar to ST131.
In the current study, we investigated the epidemiology of third-generation
cephalosporin- and carbapenem-resistant ST410 E. coli isolates from Danish patients, to
elucidate whether multidrug-resistant ST410 was causing national outbreaks or, alter-
natively, if a global clone was being introduced multiple times. We further aimed to set
ST410 into a global context by the addition of genome data from other national
collections as well as from publicly available genomes extracted from the EnteroBase
(http://enterobase.warwick.ac.uk) database to provide further insight into the acquisi-
tions of the carbapenemase genes blaOXA-181 and blaNDM-5 of this successful lineage.
(The data were partly presented at DANMAP 2014, DANMAP 2015, and DANMAP
2016.)
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RESULTS
Genotypic characterization. Genotypic characterization was applied to the 127
E. coli ST410 genomes included in the study (49 genomes, collected from 46 patients
from the national Danish surveillance program DANMAP, and 78 international ge-
nomes), including whole-genome sequencing (WGS)-based resistance gene proﬁling,
subtyping by ﬁmH allelic variation, and identiﬁcation of plasmid replicons and plasmid
multilocus sequence typing (pMLST) subtypes (see Table S1 in the supplemental
material).
Of the 127 ST410 genomes, 114 genomes contained at least one of 14 different ESBL
genes, plasmid-mediated AmpC (pAmpC) genes, or carbapenemase genes or a trun-
cated pAmpC gene, whereas no gene was detected in 13 genomes (Table 1). The
majority of the genomes carried blaCTX-M-15 (66%), followed by blaOXA-181 (53%),
blaCMY-2 (48%), blaNDM-5 (13%), and blaCMY-42 (10%) (Table 1).
From the analysis of the quinolone resistance-determining regions (QRDRs) in the
127 ST410 genomes, 115 of the genomes had S83L and D87N amino acid substitutions
in gyrA, S80I substitution in parC, and S458A substitution in parE. None of the 127
genomes had amino acid changes in the QRDR of gyrB (Table S1).
Two genomes from the United States (SAMN06645838 and SAMN02442857) and
one genome from Denmark (SAMN01885884) belonged to ﬁmH53 (H53). The remaining
124 genomes belonged to ﬁmH24 (H24) (Table S1).
Of the 127 ST410 genomes, 66 (52%) had an IncX3 replicon and 125 (98%) had an
IncF replicon, with the majority (58/125, 46%) belonging to pMLST F1:A1:B49, while 24
TABLE 1 Combination of extended-spectrum -lactamase, pAmpC, and carbapenemase enzymes in the 127 Escherichia coli ST410
genomes
Phenotype Gene No. of genomes % of genomes
None No gene detected 13 10
ESBL blaCTX-M-15 21 17
blaCTX-M-1 2 2
blaSHV-12 1 1
blaCTX-M-1/blaCTX-M-15 1 1
pAmpC blaCMY-42 7 6
blaCMY-2 1 1
Carbapenemase blaOXA-181 1 1
ESBL/pAmpC blaCTX-M-15/blaCMY-2 1 1
blaCTX-M-15/blaCMY-42/blaDHA-1 1 1
ESBL/carbapenemase blaCTX-M-15/blaOXA-181 3 2
blaCTX-M-15/blaKPC-2 2 2
blaCTX-M-15/blaNDM-1 1 1
blaCTX-M-15/blaKPC-3 2 2
blaCTX-M-15/blaOXA-48 1 1
blaTEM-30/blaKPC-3 2 2
pAmpC/carbapenemase blaCMY-2/blaOXA-181 11 9
blaCMY-2/blaNDM-5 1 1
blaCMY-42/blaOXA-181 1 1
blaDHA-1/blaOXA-48 1 1
blaCMY-2/blaNDM-5/blaOXA-181 2 2
ESBL/pAmpC/carbapenemase blaCTX-M-15/blaCMY-2/blaOXA-181 29 23
blaCTX-M-15/blaCMY-42/blaOXA-181 3 2
blaCTX-M-15/blaCMY-2-truncated/blaOXA-181 2 2
blaCTX-M-15/blaCMY-42/blaOXA-48 1 1
blaCTX-M-15/blaCMY-2/blaNDM-5/blaOXA-181 9 7
blaCTX-M-15/blaCMY-2/blaNDM-4/blaOXA-181 3 2
blaCTX-M-15/blaSHV-12/blaCMY-2/blaNDM-5 1 1
blaCTX-M-15/blaSHV-12/blaCMY-2/blaNDM-5/blaOXA-181 3 2
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(19%) belonged to F36:A4:B1, seven (6%) belonged to F31:A4:B1, six (5%) belonged to
F48:A1:B49, and three (2%) belonged to F2:A4:B1. For the remaining 27 genomes, 23
different pMLSTs were identiﬁed (Table S1).
Epidemiology of E. coli ST410 in Denmark. The epidemiology of the 49 ST410
isolates from the Danish surveillance program was investigated by single nucleotide
polymorphism (SNP) analysis and visualized with the metadata year of isolation,
third-generation cephalosporin resistance (3GC-R) genes, and IncX3 and IncF replicons
in a phylogenetic tree (Fig. 1). For construction of the phylogenetic tree, 721 SNPs were
identiﬁed between the 49 genomes, based on 86% of the reference chromosome after
removal of recombinant regions.
The SNP analysis was used to identify possible clones (PC) within the ST410 national
Danish strain collection. A pairwise comparison of the SNP differences across the
isolates (Fig. S1A) showed a group of isolates with no more than 40 SNPs to the nearest
neighbor (0 to 41 SNPs in pairwise comparison), two isolates with 80 SNPs between the
genomes, and the remainder with more than 150 SNPs to the nearest neighbor.
Adhering to an SNP distance of 40 SNPs to the nearest neighboring isolate for
describing possible clones (PC40) (Table 2) resulted in four PC40s (PC40-1, -2, -3, and -4).
Additionally, possible outbreaks (PO; clusters containing at least three individual iso-
lates) were identiﬁed by adhering to an SNP distance of 10 SNPs to the nearest
FIG 1 Rooted maximum likelihood phylogeny constructed with Gubbins based on SNP alignment of 49 Danish E. coli ST410 genomes. For each
isolate, the following metadata are included: year of isolation, associated third-generation cephalosporin resistance (3GC resistance), and presence
of IncFIA, IncFIB, IncFII, and IncX3 replicons. Possible clones and outbreaks are colored as per the key.
Roer et al.
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neighboring isolate (PO10). Based on this cutoff value, ﬁve possible outbreaks were
identiﬁed (PO10-1, -2, -3, -4, and -5) (Fig. 1).
PC40-1 encompassed three genomes with 0 to 4 SNP differences, thus also indicating
a possible outbreak (PO10-1). The three isolates were from 2015 (n  1) and 2016 (n 
2); all three genomes contained the blaCTX-M-15 gene and an IncF replicon with pMLST
F36:A4:B1. Travel information for the three patients was not available, but the patients
had all been hospitalized concurrently in the same hospital unit, R-2 (Fig. S3), in the
central region of Denmark (map in Fig. S2).
The second possible clone, PC40-2, included six genomes with 0 to 2 SNP differences,
also indicating a possible outbreak (PO10-2). The six isolates were from 2015 (n 5) and
2016 (n  1) and originated from ﬁve patients hospitalized in the central region of
Denmark. An IncF replicon with pMLST F48:A1:B49 and blaCMY-42 were present in 5/6
genomes. Travel information was unavailable for all ﬁve patients associated with these
six isolates. However, patients P1, P3, P4, and P5 were hospitalized concurrently at the
same hospital unit (R-8) in the beginning of June, and patients P2 and P4 also
simultaneously at R-8 in mid-June (Fig. S4).
The third possible clone (PC40-3) comprised 28 isolates, collected from patients
hospitalized in the capital region of Denmark (n 13), the Zealand region (n 10), the
southern region of Denmark (n  1), and the central region of Denmark (n  4). The
genomes carried blaCMY-2 (28/28) and blaOXA-181 (27/28); IncF replicons with pMLST
F1:A1:B49 (25/28), F1:A6:B49 (2/28), or F2:A1:B49 (1/28); and an IncX3 replicon (28/28).
PC40-3 spanned between 0 and 41 SNPs and featured three possible outbreaks, PO10-3,
PO10-4, and PO10-5, described in an epidemiological context below.
PO10-3 comprised 11 genomes with 0 to 12 SNP differences, collected from nine
patients hospitalized during 2015 (n  1), 2016 (n  5), and 2017 (n  5) in the capital
region of Denmark (n  1) and the Zealand region (n  10). For two patients, two
isolates were included: patient P3 with 11 SNP differences between the isolates
collected 13 months apart and patient P6 with three SNP differences between the
isolates collected 5 months apart. The genomes in PO10-3 carried blaNDM-5 (11/11) and
blaCTX-M-15 (8/11), and all genomes harbored IncF (pMLST F1:A1:B49) and IncX3 repli-
cons. A history of travel to Egypt was registered for P1 from 2015, whereas travel history
was unavailable for the remaining 10 patients. Patients P2 to P6 and P8 could be linked
through overlapping stays within the same hospital units, whereas patient P7 had been
hospitalized at the same hospitals units as P2 to P6 and P8 but 2 or more months apart
from the other patients (Fig. S5). No link could be established between patient P1 and
the remaining patients. For patient P9, no obvious link could be found to the remaining
TABLE 2 Possible clones and outbreaks identiﬁed in the Danish ST410 Escherichia coli collectiona
PC40
No. of
genomes
in PC40
Region(s)
(no. of
genomes)
No. of
SNPs PO10
No. of
genomes
in PO10
Region(s)
(no. of
genomes)
No. of
SNPs
Yr(s) (no. of
genomes)
Resistance enzyme(s)
(no. of genomes) Replicon(s)
PC40-1 3 Ce (3) 0–4 PO10-1 3 Ce (3) 0–4 2015 (1),
2016 (2)
CTX-M-15 IncF
PC40-2 6 Ce (6) 0–2 PO10-2 6 Ce (6) 0–2 2015 (5),
2016 (1)
CMY-2 (5) IncF
PC40-3 28 Ca (13),
Ze (10),
So (1),
Ce (4)
0–41 PO10-3 11 Ca (1),
Ze (10)
0–12 2015 (1),
2016 (5),
2017 (5)
CMY-2, OXA-181 (10),
NDM-5, CTX-M-15 (8)
IncF, IncX3
PO10-4 3 So (1),
Ca (2)
3–6 2016 (3) CMY-2, OXA-181,
CTX-M-15 (2)
IncF, IncX3
PO10-5 3 Ca (1),
Ce (2)
2–3 2015 (1),
2016 (2)
CMY-2, OXA-181,
CTX-M-15
IncF, IncX3
PC40-4 4 Ca (4) 15–38
aAbbreviations: PC40, possible clone with 40 SNPs to the nearest neighboring isolate; PO10, possible outbreak with 10 SNPs to the nearest neighboring isolate; Ce,
central region of Denmark; Ca, capital region of Denmark; Ze, Zealand region; So, southern region of Denmark.
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patients, but patient P9 was admitted to hospital H shortly after patient P3, though at
different units.
PO10-4 consists of three isolates with 3 to 6 SNP differences, isolated in 2016 (n 
3) in the southern region of Denmark (n  1) and the capital region of Denmark (n 
2). The genomes carried blaCTX-M-15 (2/3), and all harbored IncF (pMLST F1:A1:B49) and
IncX replicons. The three patients did not travel prior to hospitalization. Patients P1 and
P3 had been hospitalized 4 months apart in the same hospital unit, but no link could
be found to patient P2 (Fig. S6).
PO10-5 consisted of three isolates with 2 to 3 SNP differences; they were isolated in
2015 (n  1) and 2016 (n  2), in the capital region of Denmark (n  1) and the central
region of Denmark (n  2). The genomes contained blaCTX-M-15 (3/3), and all harbored
IncF (pMLST F1:A1:B49) and IncX3 replicons. A history of travel to Lebanon was
registered for P1 from 2015, while for the remaining two patients, one had no history
of recent travel and for the other information on travel history was unavailable. Patients
P1 and P3 were admitted at different hospitals, whereas patient P2 was not hospitalized
within the investigated time period (Fig. S7).
The fourth possible clone (PC40-4) included four isolates with 15 to 38 SNP differ-
ences. As the pairwise comparison showed 10 SNPs for all combinations, no regional
outbreaks were inferred for this clone. All four isolates carried an IncF replicon with
various pMLST proﬁles (F36:A4:B1, 2/4; F31:A4:B1, 1/4; or F2:A6:B33, 1/4), and two of the
isolates carried an IncX3 replicon. The isolates were from 2015 (n 2), 2016 (n 1), and
2017 (n  1) from patients hospitalized in the capital region of Denmark (n  4). Two
of the patients had a history of travel to Pakistan, while travel history was unavailable
for the remaining two patients.
E. coli ST410 in a global context. The 127 ST410 international isolates spanned
more than 4 decades (1975 to 2017) and were from 14 different countries: Denmark
(n  51); United Kingdom (n  32); United States (n  20); Germany (n  10); Canada
(n  4); Brazil (n  2); and Ireland, Japan, Nepal, Norway, Saudi Arabia, Singapore,
Sweden, and Tanzania (one isolate each).
To investigate ST410 in a global context and its temporal dissemination and
evolution, a Bayesian coalescent method was applied for phylogenetic reconstruction
of the ST410 lineage based on the genomic data and sampling time. By using a general
time-reversible (GTR) model and a strict molecular clock with a Bayesian Skyline
population model, the BEAST analysis estimated the age of the ST410 lineage to be
approximately 214 years (1803; 95% highest posterior density [HPD], 1774 to 1832)
(Fig. 2). The phylogenetic reconstruction revealed two distinct clonal lineages of ST410:
lineage A with ﬁmH53 (A/H53) and lineage B with ﬁmH24 (B/H24) (Fig. 3). The B/H24
lineage was further divided into three sublineages: B2/H24R with the introduction of
ﬂuoroquinolone resistance by mutations in gyrA and parC, B3/H24Rx with the intro-
duction of blaCTX-M-15, and B4/H24RxC with the introduction of blaOXA-181.
FIG 2 Introduction of OXA-181 and NDM-5 into E. coli ST410. Peaks in the density diagram are colored
by the introduction of the carbapenemases: green, OXA-181; blue, NDM-5.
Roer et al.
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FIG 3 Time-scaled phylogeny of E. coli ST410 (n  127) with associated third-generation cephalosporin resistance; plasmid replicons; mutations
in the QRDR of gyrA, gyrB, parC, and parE; and the possible Danish outbreaks as colored by key. Brackets at right represent ST410 clades as
described in the text. The tips of the tree to the left represent the year of isolation for the isolates, with the year stated next to the tips, which
is colored by country of isolation, as per the key. Œ, genomes isolated from sources other than human. WT, wild type.
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PC40-1, PC40-2, and PC40-4 were all part of the B3/H24Rx complex (Fig. 3). The Danish
ST410 isolates in PC40-1 and PC40-2 from the national analysis did not cluster together
with any non-Danish isolates (Fig. 3). The four Danish isolates from PC40-4 clustered
together with one isolate from the United Kingdom, one isolate from Canada, and two
isolates from the United States. For PC40-3, an additional 35 isolates clustered together
with the 28 Danish isolates, resulting in a distinct clade with 63 isolates (B4/H24RxC in
Fig. 3).
PO10-4 and PO10-5 clustered in separate clades without any additional isolates,
whereas PO10-3 clustered closely with four isolates from the United Kingdom (7 to 21
SNPs to the nearest neighbor). These 63 isolates were collected between 2013 and
2017, in Denmark (n  29), the United Kingdom (n  29), Canada (n  3), Norway (n 
1), and Sweden (n  1). Additionally, 47 of the isolates in B4/H24RxC carried blaOXA-181,
two isolates carried blaNDM-5, and 14 isolates carried both carbapenemases.
Introduction of blaOXA-181 and blaNDM-5 into ST410. The timing of introductions
of blaOXA-181 and blaNDM-5 into B4/H24RxC was predicted using BEAST (Fig. 3). The
introduction of blaOXA-181 was estimated to have occurred approximately 14 years ago
(2003; 95% HPD, 2000 to 2005), with the subsequent introduction of blaNDM-5 3.5 years
ago (2014; 95% HPD, 2013 to 2014).
To investigate if blaOXA-181 was carried on an IncX3 plasmid, the genome scaffolds
of the 63 ST410 genomes in B4/H24RxC with blaOXA-181 and/or IncX3 and an additional
six genomes with blaOXA-181 and/or IncX3 were compared with the complete plasmid
sequence of pAMA1167-OXA-181 from E. coli ST410 (10) (Fig. S8A). Overall, the results
indicated that the plasmid harboring blaOXA-181 is well preserved; only one blaOXA-181-
positive ST410 isolate, from the United Kingdom, did not carry the IncX3 plasmid (the
outermost ring, H14352020701). Additionally, two isolates from Denmark harbored
the IncX3 backbone but did not carry the blaOXA-181 gene (CPO20150034 and
CPO20170049).
To investigate if blaNDM-5 was introduced via an IncF plasmid with pMLST F1:A1:B49,
the 58 ST410 draft genomes with blaNDM-5 and/or IncF with pMLST F1:A1:B49 were
compared with the complete plasmid sequence of pAMA1167-NDM-5 (11) (Fig. S8B). All
58 isolates carried genomic information, which covered major parts of the pAMA1167-
NDM-5 plasmid backbone, regardless of their blaNDM-5 gene status. However, among
the 16 blaNDM-5-positive genomes, the IncF backbone revealed even higher similarity.
The 11 Danish ST410 isolates from PO10-3, and four United Kingdom isolates clustering
near the PO10-3 group, all carried similar IncF backbones (15 innermost rings in Fig. S8B
[see also Fig. S9]). However, some of the plasmids lacked various resistance genes,
including one United Kingdom isolate (ring 12 from the middle, H15074073205)
missing the blaNDM-5 gene. Finally, three of the United Kingdom isolates carried
blaNDM-4 (from the middle; ring 22, H14148045301; 24, H14142058201; and 25,
H14140075501) on a plasmid very similar to the blaNDM-5 plasmid found in the PO10-3
isolates.
DISCUSSION
Recent studies indicate that E. coli ST410 is another successful pandemic extraint-
estinal pathogenic E. coli (ExPEC) lineage similar to ST131 (5, 16). Our ﬁndings support
this hypothesis; however, as national surveillance programs monitor only local epide-
miology, global surveillance is required to follow the dissemination of pandemic clones.
The limited number of studies on how to interpret phylogenetic relatedness based on
SNP differences in E. coli makes it difﬁcult to give a generic threshold on how to
distinguish clones from local or regional outbreaks when epidemiological data are not
available (17–19). Accessing the national collection of E. coli ST410 from Denmark, a
cutoff value of no more than 40 SNP differences to the nearest neighbor seemed to
deﬁne clones within this collection, as the closest genome differed by 159 to 185 SNPs
to PC40-1 to -4 (see Fig. S1B in the supplemental material). The deﬁnition of outbreaks
being 10 or fewer SNP differences apart from the nearest neighbor has previously been
shown plausible (9) and was thus used in this study. Breakdown into possible outbreaks
Roer et al.
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(10 SNPs) revealed ﬁve possible ST410 outbreaks (PO10s) in Denmark during 2015 to
mid-2017. Two of these, PO10-1 and PO10-2, carried blaCTX-M-15 and blaCMY-42, respec-
tively. Travel history for all patients in these two PO10s was unavailable, and comparison
with the genomes collected from EnteroBase did not reveal any links to other countries.
Isolates within these two PO10s were collected from patients within the same region.
Epidemiological investigation revealed links between the patients indicating that both
could be true outbreaks. This is further supported by the global analysis, where the
Danish outbreaks cluster in distinct clades (Fig. 3).
The possible clone PC40-3, including PO10-3, -4, and -5, consisted of 28 isolates with
0 to 41 SNP differences, and most of the isolates carried blaCTX-M-15, blaCMY-2, and
blaOXA-181. Regarding PO10-4 and PO10-5, no epidemiological link could be made
between the patients within the possible outbreaks. In PO10-4, the patients did not
travel prior to hospitalization, and in PO10-5, one patient had recent travel activity to
Lebanon, one patient did not report travel, and travel history was unavailable for the
last patient. Thus, it is unclear if multiple introductions occurred, or if unknown carriers
or contaminated environmental sources could link the spread between patients from
these two PO10s.
Further analysis revealed another possible outbreak (PO10-3) involving 11 isolates
from nine patients (P1 to P9), where one patient (P6) contributed with two samples
isolated 5 months apart and one patient (P3) contributed with two samples 13 months
apart. Isolates from PO10-3 had an additional carbapenemase gene, blaNDM-5. An
epidemiological link was found among patients P2 to P8. The patient P9 could possibly
be linked to this outbreak via hospital H. We were unable to link patient P1 to the other
patients. However, it is not possible to exclude an unknown carrier of the clone, nor an
unregistered travel link for patients P2 to P9, whereas patient P1, with the isolate from
2015 (AMA1167), had traveled to Egypt prior to isolation of AMA1167 (10). Also in 2015,
an E. coli ST410 isolate harboring blaCTX-M-15 and blaCMY-2 and carrying blaOXA-181 on an
~48.5-kb plasmid and blaNDM-5 on an ~100-kb plasmid together with FIA and FIB
replicons was reported in a study from Egypt (20). The characteristics of this Egyptian
OXA-181/NDM-5-producing ST410 isolate correlate with the ﬁrst OXA-181/NDM-5-
producing ST410 isolate collected in Denmark, suggesting that the Danish patient, P1,
most likely acquired the isolate during travel to Egypt in 2015. Unfortunately, no WGS
data are available for the Egyptian isolate to evaluate such a link.
From the global analysis, the close genetic relationship between four ST410 isolates
isolated in the United Kingdom and the genomes from Danish ST410 isolates from
PO10-3 could indicate a similar introduction to the United Kingdom; however, two of
the patients from the United Kingdom reported no travel prior to hospitalization, and
for the remaining two, travel information was unavailable. Similar genetic proﬁles have
previously been reported for NDM-producing E. coli ST410 isolates obtained from
patients in Denmark and the United Kingdom (21), indicating either similar travel
patterns by inhabitants of the two countries or direct transmission between the
countries. However, comprehensive epidemiological data with travel information are
needed on a global scale to clarify the actual route of transmission.
The coalescence analysis (Fig. 2 and 3) on the global collection of 127 ST410 isolates
indicated a most recent common ancestor approximately 214 years ago (the early
1800s), with conﬁdence intervals stretching 30 years backward and forward. In com-
parison, the time to the most recent common ancestor for the ST131 clade was
estimated as the late 1800s (22). Therefore, compared with ST131, ST410 is predicted to
be a slightly older lineage of E. coli, even though the prevalence of ST131 is far higher
than that of ST410.
Several studies have investigated the population structure of ST131 with WGS data
and found a sublineage, C/H30, deﬁned by the presence of the ﬁmH30 allele. Within the
C/H30 lineage, the C1/H30R clade, possessing ﬂuoroquinolone resistance conferred by
mutations in the chromosomal genes gyrA and parC, and the C2/H30Rx clade, which in
addition is associated with carriage of blaCTX-M-15, emerged around 1987 (3, 4, 22, 23).
We identiﬁed a similar population structure of ST410, with two sublineages based on
E. coli ST410 International High-Risk Clones
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the ﬁmH alleles: A/H53 (3/127 genomes) and B/H24 (124/127 genomes). In the B/H24
sublineage, the introduction of the ﬂuoroquinolone resistance by mutations in gyrA and
parC (B2/H24R) and the introduction of blaCTX-M-15 (B3/H24Rx) were also estimated to
have occurred around 1987 concurrently with the widespread clinical introduction of
extended-spectrum cephalosporins and ﬂuoroquinolones (Fig. 3). Additionally, the
introduction of blaCTX-M-15 seems to be related to the acquisition and persistence of an
IncFII plasmid harboring FIA/FIB replicons, which was also observed in ST131 (22). In
ST410, the introduction of blaOXA-181 on an IncX3 plasmid was predicted to have
occurred around 2003 (Fig. 3). Furthermore, introduction of blaNDM-5, likely on an IncF
replicon, around 3.5 years ago, resulted in a highly resistant clone causing an outbreak
(PO10-3) in Denmark.
The majority of the 127 international ST410 isolates in our study were collected from
humans (119/127); however, eight isolates were from nonhuman sources. The genomes
obtained from isolates from swine (n  2), poultry (n  2), and air from poultry houses
(n  2) were all located in the nonresistant clades A/H53 and B1/H24 (Fig. 3), whereas
the genomes obtained from sewage and from a dog were both located in the B3/H24Rx
cluster. The latter cases likely represent the shared environment with humans. In our
study, isolates found in the carbapenemase clade B4/H24RxC were all of human origin.
However, carbapenemase genes are often located on mobile genetic elements (13, 14),
together with other resistance genes encoding resistance to antibiotic classes com-
monly used in veterinary medicine (e.g., tetracycline, sulfonamides, or phenicols). Thus,
once introduced in animals, carbapenemase genes may be coselected by the use of
other classes of antibiotics, which could increase the prevalence of CPE in animals.
CPE is a worrisome risk in public health due to the multidrug resistance and the
potential for dissemination to multiple sources, including transmission from patient
to patient. The mobile colistin resistance gene mcr-1 has been reported in ESBL-
producing E. coli ST410 in Brazil (24) and Germany (25) but was not observed in our
127 isolates. This demonstrates the potential of ST410 to acquire further resistance
determinants, leaving very limited therapeutic agents for treating life-threatening
bacterial infections.
ST410 E. coli represent a globally distributed lineage isolated in Europe, North
America, South America, Asia, and Africa and associated with various antimicrobial
resistance determinants, including ESBLs, pAmpCs, carbapenemases, and colistin resis-
tance genes. Moreover, our data indicate that ST410 has the ability to persist within a
host for long intervals. A subsequent sampling of two patients resulted in the detection
of two ST410 isolates in both samples, the ﬁrst patient with 11 SNP differences between
the genomes of isolates collected 13 months apart and the second patient with three
SNP differences between the genomes of isolates collected 5 months apart.
The possible outbreaks presented here and previous observations of interspecies
transmission of ST410 (5) indicate a potential for effective transmission between
patients. Additionally, among the Danish ST410 isolates, 20/49 (41%) were from blood-
stream infections, which may qualify for severe infections, and show a potential for
enhanced pathogenicity. ST410 belongs to phylogroup A, generally linked to commen-
sal colonization (26), whereas ST131 E. coli belongs to phylogroup B2, dominated by
strains associated with extraintestinal human infections, adherent-invasive E. coli (AIEC),
and enteropathogenic E. coli (EPEC) (27). Our study demonstrates that parallels can be
drawn between the phylogeny and emergence of ﬂuoroquinolone and ESBL resistance
(CTX-M-15) in ST131 and ST410. The reduced virulence coupled to phylogroup A could
explain why ST410 has not been as globally dominant as ST131, even though ST410 is
a slightly older lineage. Further studies are needed to give the complete and true
picture of the pathogenicity and ﬁtness of ST410.
These characteristics are properties of an international high-risk clone (1) and
underline that ST410 qualiﬁes as a lineage with new international multidrug-resistant
high-risk clones, which should be monitored closely in the future.
Roer et al.
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MATERIALS AND METHODS
Bacterial isolates. Initially, the strain collection at Statens Serum Institut (SSI) containing all ESBL/
pAmpC-producing E. coli isolates from human bloodstream infections and the carbapenemase-
producing organisms (CPO) collected by the Danish Departments of Clinical Microbiology (DCMs) as part
of the Danish surveillance program DANMAP between 2014 and mid-2017 were screened for E. coli
ST410. From the ESBL/pAmpC collection, 14 ST410 isolates from 2014 to 2015 published by Roer et al.
(9) and six ST410 isolates from 2016 were obtained (in total, covering 20 isolates from 19 patients). From
the CPO surveillance from January 2014 to July 2017, 29 ST410 isolates were included from 27 patients,
resulting in a total study population of 49 ST410 isolates from Danish patients. Reported travel
information was obtained from the corresponding DCMs as follows: travel-associated and country
information (if known), no recent travel activity, or information not available.
Additionally, EnteroBase (https://enterobase.warwick.ac.uk/) was searched for E. coli ST410 genomes
(accessed 3 July 2017) to extend the study with internationally available ST410 genomes to estimate
when the two carbapenemase genes blaOXA-181 and blaNDM-5 were introduced into the ST410 lineage.
Only ST410 genomic data with relevant metadata (year of collection, country, and source type) and
availability of raw reads were included. The selection criteria resulted in 43 international E. coli genomes:
36 reported to have been collected from humans, two collected from swine, two collected from poultry,
two air samples from poultry houses, and one from sewage (see Table S1 in the supplemental material).
Finally, sequences from other national surveillance programs with available genome data were included
in the study to expand the number and diversity of ST410 genomes harboring blaOXA-181 with or without
blaNDM-5. Raw reads from 32 genomes were included from the United Kingdom of human origin, one
genome from Germany collected from a dog, and one genome each from Norway and from Sweden,
both of human origin, resulting in 127 ST410 genomes with relevant metadata and raw reads available
for further analysis (Table S1).
Whole-genome sequencing. For isolates that were part of DANMAP surveillance, genomic DNA was
extracted (DNeasy Blood and Tissue kit; Qiagen, Copenhagen, Denmark), with subsequent library
construction (Nextera kit; Illumina, Little Chesterford, United Kingdom) and ﬁnally WGS (MiSeq or
NextSeq; Illumina) according to the manufacturer’s instructions to obtain paired-end reads of 2 by 250
or 2 by 150 bp in length.
The raw reads of all 127 isolates were assembled into draft genomes using the SPAdes assembler v.
3.10.1 (28).
Genotypic characterization. Draft genomes for the 127 ST410 isolates were submitted to the Center
for Genomic Epidemiology (CGE) server through the batch uploader developed for the Bacterial Analysis
Platform (BAP) (https://cge.cbs.dtu.dk/services/cge/) (29) and analyzed using the CGE tools described
below (analysis performed between 14 August 2017 and 24 August 2017).
(i) Resistance genes and mutations in the QRDRs. Resistance genes were identiﬁed with ResFinder
2.1 (30) (included in the CGE BAP), using a threshold of 100% identity (ID) for identifying genes encoding
-lactamases and carbapenemases and 98.00% ID for all other genes encoding transferable antimicrobial
resistance. For phenotypically resistant isolates without -lactamase- and carbapenemase-encoding
genes or isolates with less than 100% identity, KmerResistance 1.0 (https://cge.cbs.dtu.dk/services/
KmerFinder/) (31) was used to conﬁrm the presence/absence of the gene(s).
To identify mutations in the QRDRs, a nucleotide BLAST database of the 127 ST410 genomes was set
up using BLAST 2.6.0 (32). Gene sequences of gyrA, gyrB, parC, and parE were extracted from all
genomes by performing a BLASTN query of a representative nucleotide sequence for each of the four
genes against this database. The nucleotide sequences were translated into corresponding amino acid
sequences based on standard genetic code, using the reading frame beginning from the start codon.
Amino acid changes were identiﬁed in the QRDRs (GyrA, amino acid position 67 to 106 [33]; GyrB, amino
acid position 331 to 480 [34]; ParC, amino acid position 38 to 169 [35]; and ParE, amino acid position 365
to 525 [36]) for each gene by comparison with the wild-type gene variants of the quinolone- and
ﬂuoroquinolone-susceptible E. coli K-12 MG1655 (GenBank accession no. NC_000913.3).
(ii) Typing of isolates. Multilocus sequence type (MLST) was extracted with MLST 1.6 (37), as part of
the CGE BAP, to verify that the genomes belonged to ST410 in the Achtman scheme (MLST 1) (38).
ﬁmH subtypes were identiﬁed with FimTyper 1.0 (https://cge.cbs.dtu.dk/services/FimTyper/) (39).
(iii) Plasmid analysis. IncF and IncX3 plasmid replicons were identiﬁed using PlasmidFinder 1.4 (40)
(included in CGE BAP) and further subtyped by plasmid MLST (pMLST) with the pMLST 1.4 tool (40).
The genome of the Danish ST410 isolate AMA1167 has previously been completely sequenced
(GenBank accession no. GCA_002803905.1) (10), and the complete sequences of the OXA-181 and NDM-5
plasmids were used for comparative plasmid analysis. BLAST analysis of draft genome against
pAMA1167-OXA-181 (GenBank accession no. CP024806.1) and pAMA1167-NDM-5 (GenBank accession
no. CP024805.1) was performed using the GView server (https://server.gview.ca/).
Genomic epidemiology. (i) Single nucleotide polymorphism analysis. The Northern Arizona SNP
Pipeline (NASP) v1.0.0 was used to estimate the molecular epidemiology by identifying SNPs. Brieﬂy,
duplicate regions of the reference chromosome of ST410 isolate YD786 (GenBank accession no.
NZ_CP013112.1) were identiﬁed by aligning the reference against itself with NUCmer v3.1 and masked
from downstream analysis. Raw reads of the analyzed genomes were aligned against the FASTA-
formatted reference using the Burrows-Wheeler Aligner (BWA), and SNPs were identiﬁed using GATK
UniﬁedGenotyper (41).
Gubbins v2.3.1 was used to remove recombination signals in the SNP output (42). The SNP
phylogenies were annotated with relevant metadata using iTOL (http://itol.embl.de) (43).
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(ii) Identiﬁcation of possible clones, outbreaks, and patient links. Possible clones (PC) in the
Danish collection were predicted based on the distribution of the pairwise SNP differences between the
isolates. Possible clonal outbreaks were identiﬁed for clusters containing at least three individual isolates,
by adhering to an SNP distance of 10 SNPs to the nearest neighboring isolate (PO10), as previously
described (9).
Patient links in the different possible outbreaks (PO10s) were investigated 6 months prior to the ﬁrst
identiﬁed isolate in the respective PO10 and 6 months after the last identiﬁed isolate. Hospital admissions
(hospital, unit, and time of admission) were used to construct the timeframe and possible routes of
transmission for the PO10s.
(iii) Coalescence-based analyses. BEAST analysis was conducted to reconstruct the global phylog-
eny of ST410 based on the SNP data generated from the 127 raw sequence data sets, for estimation of
the time points wherein blaOXA-181 and blaNDM-5 were acquired by the ST410 lineage. For deﬁning the two
groups for blaOXA-181 and blaNDM-5, a maximum likelihood phylogeny was estimated with PhyML 3.0 by
using the Bayesian information criterion with BIONJ as initial tree, nearest neighbor interchange (NNI) as
type of tree improvement, and a bootstrap value of 100 (44). Based on the phylogeny, the two groups
were deﬁned.
The timing of the acquisitions of blaOXA-181 and blaNDM-5 was inferred using coalescence-based
analyses in BEAST 1.8.4 at CIPRES Science Gateway (https://www.phylo.org) using duplicate runs.
Analyses were performed using different substitution models (general time-reversible [GTR] and
Hasegawa-Kishino-Yano [HKY]), strict and relaxed molecular clock, and different demographic models
including Bayesian Skyline, constant population, and exponentially growing population tree priors.
Chains were sampled every 40,000th step during the 400 million Markov chain Monte Carlo (MCMC)
steps. The ﬁrst 10% of each chain was discarded as burn-in. The best model was selected based on Bayes
factor (BF) comparison (45). Data were analyzed with Tracer v1.5 and TreeAnnotator v1.8.4, and the trees
were depicted by using iTOL (http://itol.embl.de/) (43).
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